The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic ...

Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase inhibitor for the adjuvant treatment of adults with stage II-III early breast ...

EULAR now recommends moving directly to biologic or targeted synthetic disease-modifying antirheumatic drugs if the initial ...

After its $1 billion acquisition by Novartis, Mariana Oncology is expanding its Massachusetts real estate. Biotech's Future - ...

CRISPR Therapeutics’ CRSP first marketed product is the one-shot gene therapy Casgevy, approved in late 2023 and early 2024 ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 19, 2025 /EINPresswire.com/ -- The market for Paroxysmal Nocturnal Hemoglobinuria PNH and Atypical Hemolytic Uremic Syndrome aHUS has seen remarkable ...

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...

Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal.

Novartis AG has disclosed huntingtin (HTT; HD) (mutant) splicing modulators reported to be useful for the treatment of familial dysautonomia, Huntington’s disease and spinal muscular atrophy.

In its continued bid to waylay the launch of MSN Pharmaceuticals’ proposed Entresto generic, Novartis has told a federal ...

Based in Basel, Novartis (NVS) is in the Medical sector, and so far this year, shares have seen a price change of 21.05%. Currently paying a dividend of $2.6 per share, the company has a dividend ...